GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2 | affects expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Daunorubicin affects the expression of BCL2 mRNA | PMID:27780733 | Bcl2 | decreases expression | ISO | Bcl2 (Rattus norvegicus) | 6480464 | CTD | Daunorubicin results in decreased expression of BCL2 protein | PMID:37178933 | Bcl2 | decreases expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Daunorubicin results in decreased expression of BCL2 mRNA | PMID:19421372 | Bcl2 | decreases response to substance | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | BCL2 results in decreased susceptibility to Daunorubicin | PMID:21595920 | Bcl2 | multiple interactions | ISO | Bcl2 (Rattus norvegicus) | 6480464 | CTD | TRPC6 protein promotes the reaction [Daunorubicin results in decreased expression of BCL2 protein] | PMID:37178933 | Bcl2 | multiple interactions | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in decreased expression of BCL2 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein]; bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]; bromotetrandrine promotes the reaction [Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA] | PMID:19421372 PMID:19918366 PMID:21302442 PMID:21720514 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |